Company Profile

Aravive, Inc. is a clinical-stage oncology company. The Company is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The Company's lead product candidate, Batiraxcept, is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase III trial in platinum-resistant ovarian cancer (NCT04729608), a Phase Ib/II trial in clear cell renal cell carcinoma (NCT04300140), and a Phase Ib/II trial in pancreatic adenocarcinoma (NCT04983407).

Employees

Sector

Biotechnology & Medical Research

More about the company

31/01/24	Aravive, Inc.(NasdaqGS:ARAV) dropped from S&P TMI Index	CI
26/01/24	Aravive, Inc.(NasdaqGS:ARAV) dropped from NASDAQ Composite Index	CI
19/01/24	Wall Street Set to Open Higher Friday Ahead of Consumer Sentiment, Home Sales Data	MT
17/01/24	Aravive Shares Sink 53% After Hours on Plans to Voluntarily Terminate Listing on Nasdaq Global Select Market	MT
17/01/24	Aravive, Inc. Announces Termination of Rudy C. Howard as Chief Financial Officer	CI
17/01/24	Aravive, Inc. Announces Termination of Gail McIntrye as Chief Executive Officer	CI
17/01/24	Aravive, Inc. Announces Board and Committee Resignations	CI
09/11/23	Aravive, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
22/08/23	Cantor Fitzgerald Downgrades Aravive to Neutral From Overweight, Adjusts Price Target to $0.25 From $18	MT
21/08/23	Aravive, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
03/08/23	Top Midday Decliners	MT
03/08/23	EF Hutton Downgrades Aravive to Hold From Buy, Adjusts Price Target to $1 From $10	MT
03/08/23	HC Wainwright Downgrades Aravive to Neutral From Buy	MT

22/08/23	Cantor Fitzgerald Downgrades Aravive to Neutral From Overweight, Adjusts Price Target to $0.25 From $18	MT
03/08/23	EF Hutton Downgrades Aravive to Hold From Buy, Adjusts Price Target to $1 From $10	MT
03/08/23	HC Wainwright Downgrades Aravive to Neutral From Buy	MT
03/08/23	William Blair Downgrades Aravive to Market Perform From Outperform	MT
03/08/23	BTIG Downgrades Aravive to Neutral From Buy	MT

17/01/24	Aravive, Inc. to Delist from The Nasdaq Stock Market	AQ
19/10/23	The Street Reports: Guide to Penny Stocks Look Now! CLNV, ARAV, RDHL, ATHX, EPAZ	AQ
02/08/23	Aravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian Cancer	AQ
28/07/23	Aravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023	AQ
14/07/23	Aravive to Participate in William Blair’s Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023	AQ

Manager	Title	Age	Since
Marek Ciszewski IRC	Investor Relations Contact	-	-
Maria Petrini PRN	Corporate Officer/Principal	-	09/04/2023

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/04/23	Maria Petrini	Free	Executive/Senior Manager	400,000	0.6684%
01/02/23	Robert B. Geller	Free	Chief Technology Officer	400,000	0.6686%
01/02/23	Leonard Dove	Free	Chief Operating Officer	400,000	0.6686%

Aravive, Inc. Share Price

Stocks

ARAV

US03890D1081

Biotechnology & Medical Research

Latest news: Aravive, Inc.

Analysts' recommendations: Aravive, Inc.

Press Releases: Aravive, Inc.

Quotes and Performance

Managers and Directors: Aravive, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARAVIVE, INC.	-13.39%	-23.18%	-	-	2.95M
WUXI APPTEC CO., LTD.	+0.79%	-6.46%	+52.86%	+71.34%	65.83B
LONZA GROUP AG	+1.92%	+8.89%	+12.90%	+82.75%	51.87B
ARGENX SE	+6.91%	+6.41%	+9.61%	+73.07%	51.2B
IQVIA HOLDINGS INC.	+0.74%	+2.75%	+26.31%	+45.29%	43.76B
BEONE MEDICINES AG	+3.87%	+10.15%	+20.69%	+132.73%	42.09B
REVOLUTION MEDICINES, INC.	+7.91%	+4.30%	+263.91%	+602.72%	39.04B
CELLTRION, INC.	-0.40%	+9.42%	+18.44%	+59.06%	34B
WUXI BIOLOGICS (CAYMAN) INC.	+3.84%	-4.94%	+42.35%	+8.92%	25.2B
GENMAB A/S	+2.36%	+4.62%	+24.20%	+31.02%	22.8B
Average	+1.46%	+0.51%	+52.36%	+122.99%	41.76B
Weighted average by Cap.	+3.06%	+0.62%	+51.12%	+124.45%